FreeStyle Libre 2 Authorized for Use in the U.S.
On June 15, 2020, Abbott announced that the FDA has authorized the FreeStyle Libre 2 System. The Libre 2 gained its CE Mark clearance in Europe late 2018 and is now authorized for adults and children 4 and up in the United States. The FreeStyle Libre 2 is a 14 day continuous glucose monitor (CGM) […]
University of Michigan Establishes Elizabeth Weiser Caswell Diabetes Institute
Named for Breakthrough T1D Research Committee member Elizabeth Caswell, Institute will support diabetes research and development of life-changing diabetes therapies.
ADA’s Scientific Sessions: Day 3
The American Diabetes Association’s Scientific Sessions is here! Until June 16, scientists will present some of the most updated topics, from beta cell replacement to regeneration and glucose and complications trials, all with the result to change things for the type 1 diabetes (T1D) community. Here is Dr. Chantal Mathieu to share her key takeaways […]
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two years—the onset of type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of […]
ADA’s Scientific Sessions: Day 2
The American Diabetes Association’s Scientific Sessions is here! Until June 16, scientists will present some of the most updated topics, from beta cell replacement to regeneration and glucose and complications trials, all with the result to change things for the type 1 diabetes (T1D) community. Here are Drs. Eric Triplett, Randi Streisand, Hubert Tse and […]
Snails—Yes, Snails—Are Helping Unlock Faster Insulins
Scientists have uncovered a potential breakthrough in developing a faster acting insulin in an unusual place: snails. Now, Breakthrough T1D-funded researchers are using the molecular features of the snail insulin to create ultra-rapid insulins for people with type 1 diabetes (T1D) and have published their findings in . As discussed in last year’s blog, certain […]
Breakthrough T1D Top Advances Over the Past Year
At Breakthrough T1D, we are committed to funding the development of new therapies to keep people with type 1 diabetes (T1D) healthier, longer, until cures are found. We saw an incredible number of key advances that have both improved the lives of those living with the disease today and that have taken us so much […]
From the Archives: Mapping Directions for Diabetes Research
A historical account about a past initiative that would help pave the way for Breakthrough T1D’s future approach to identifying research priorities.
Dr. Jane Buckner Discusses Hydroxychloroquine T1D Prevention Study
Details about the TrialNet study, including why Hydroxychloroquine, and the status of subject participation.
Viacyte Receives Funding to Continue Developing Beta Cell Therapies
ViaCyte, a regenerative medicine company long-supported by Breakthrough T1D, today announced $27 million in financing to continue the development of beta cell therapies for diabetes. This funding ensures that Viacyte’s innovative approaches to replacing the insulin-producing beta cells in people with type 1 diabetes (T1D) will keep progressing. “Beta cell therapies are a key component […]
